Core Insights - The eleventh round of national organized drug procurement has selected 55 drugs, enhancing accessibility and affordability for patients [1][2] - The procurement aims to stabilize clinical use and ensure drug quality while preventing excessive competition and collusion among companies [3][4] Group 1: Procurement Details - A total of 4.6 million medical institutions participated, with 445 companies submitting bids, resulting in 453 products from 272 companies being shortlisted [1] - Key selected drugs include Dapagliflozin and Pravastatin, both of which achieved over 1 billion yuan in sales in 2024 [1] - The procurement process has successfully completed 11 rounds, acquiring a total of 490 drugs [2] Group 2: Market Competition and Pricing - The procurement introduced measures to prevent excessive competition, such as not collecting bids for products priced below 10 million yuan and setting a price anchor at 50% of the average price [3][4] - The average price difference for selected products has decreased compared to previous rounds, indicating a more stable pricing environment [3] - The procurement rules restrict any single company from winning more than 50% of the total procurement volume for a specific drug, promoting market diversity [6] Group 3: Clinical and Quality Assurance - The procurement process allows medical institutions to report quantities based on either generic names or specific brands, with 77% of institutions opting for brand reporting [5][6] - The focus on children's medication has been emphasized, with adjustments made to ensure the availability of suitable formulations for pediatric patients [7] - Stringent quality control measures are in place, including consistency evaluations and increased regulatory oversight for low-bid companies [8] Group 4: Industry Impact - The procurement is expected to indirectly support innovation by stabilizing profits for generic drugs, allowing companies to invest in research and development [8] - The introduction of a "revival mechanism" for non-selected bids provides companies with a second chance to secure market share, reducing market volatility [8] - The industry is witnessing a shift towards innovation, with an increasing number of companies focusing on developing new drugs rather than solely relying on generics [8]

Core Viewpoint - The article discusses the results of the 11th batch of national organized drug procurement in China, highlighting the inclusion of 55 commonly used drugs across various therapeutic areas, aiming to enhance drug accessibility and affordability for patients [1][2]. Group 1: Procurement Results - The 11th batch of drug procurement included 55 drugs, with participation from 4.6 million medical institutions and 445 companies submitting bids, resulting in 453 products from 272 companies being shortlisted [1]. - Notable shortlisted drugs include Dapagliflozin, Pravastatin, and Metformin combined with Ertugliflozin, which are expected to further improve accessibility due to their inclusion in the procurement [1]. Group 2: Market Dynamics - The procurement aims to stabilize clinical use, ensure quality, and prevent excessive competition among companies, which has been a concern in previous rounds [5][6]. - The introduction of price anchors and measures to prevent collusion among related companies has led to a more stable pricing environment, with overall pricing reported as normal and stable [6][8]. Group 3: Clinical and Quality Assurance - The procurement process has been optimized to respect clinical needs, allowing institutions to report quantities based on either generic names or specific brands, with 77% of institutions opting for brand reporting [8][9]. - Measures to ensure drug quality include mandatory consistency evaluations and stringent penalties for non-compliance, ensuring that low prices do not compromise quality [10]. Group 4: Industry Impact - The procurement process is seen as a way to balance profits from generic drugs while encouraging innovation, as companies are now more inclined to invest in research and development due to stable cash flows from guaranteed procurement [11][12]. - The introduction of a "revival mechanism" allows companies that do not win bids to still secure a portion of the market, promoting a more competitive environment [11].

21世纪经济报道记者韩利明 2025年10月27日，第十一批国家组织药品集中带量采购产生中选结果。本次集采共纳入55种药品，覆盖抗感染、抗过敏、抗肿瘤、降血糖、降 血压、降血脂、消炎镇痛等领域常用药品，全国共4.6万家医药机构参加报量，445家企业的794个产品参与投标，其中272家企业的453个产品 获得拟中选资格。 国家组织药品联合采购办公室披露的拟中选结果显示，多个市场关注度较高的品种中，Hetero Labs、南京方生和医药、山东鲁抗医药 （600789）、北京伟林恒昌医药等拟中选达格列净口服常释剂型；南京道群医药、上海现代制药、瀚晖制药等拟中选普伐他汀口服常释剂型； 常州市阳光药业、齐鲁制药等拟中选二甲双胍恩格列净片(I)…… 其中，作为一种新型的抗糖尿病药物，达格列净在2019年通过国家医保谈判纳入医保乙类目录；药智数据显示，达格列净、普伐他汀在2024年 均实现全终端销售额超10亿元，此次纳入集采将进一步提升药品的可及性。 据了解，截至目前，国家医保局共开展十一批国家组织药品集采，成功采购490种药品。本次集采总体实现"稳临床、保质量、反内卷、防围 标"预期目标，拟中选结果公示后将正式发布，预计 ...

Core Insights - The article emphasizes that being the "first" in the biopharmaceutical industry does not guarantee long-term commercial success, as evidenced by the rapid evolution and competition in the market [1][3] - There is a growing recognition that "Best in Class" (BIC) products, which are iterations of existing drugs, may offer better commercial viability compared to "First in Class" (FIC) products [1][5] - The article highlights the importance of strategic innovation, particularly in the context of established mechanisms and pathways, to meet clinical needs and market demands [1][7] Group 1: Innovation Dynamics - The rapid iteration of drugs is compressing their lifecycle, forcing companies to maximize the value of new drugs within limited timeframes [1][9] - The success of atorvastatin, which became a blockbuster despite being a later entrant in the statin class, illustrates that FIC advantages can diminish over time as BIC products emerge [3][4] - Companies like Eli Lilly have successfully adopted a strategy focused on "me better" drugs, which are improvements on existing therapies rather than entirely new innovations [5][6] Group 2: Market Trends - The trend towards BIC products is evident in various therapeutic areas, including oncology and autoimmune diseases, where companies are focusing on improving established targets rather than pursuing new ones [7][9] - The competitive landscape is shifting as more Chinese pharmaceutical companies leverage their advantages in speed and cost-effectiveness to innovate rapidly, challenging established players [10] - The urgency to fill gaps left by patent expirations is leading to a preference for iteratively developed products based on validated mechanisms [9][10]